PHAR vs. ALVO, MTSR, CPRX, VKTX, KYMR, CRNX, MLTX, MOR, IMVT, and HCM
Should you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Alvotech (ALVO), Metsera (MTSR), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), MoonLake Immunotherapeutics (MLTX), MorphoSys (MOR), Immunovant (IMVT), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.
Pharming Group vs. Its Competitors
Alvotech (NASDAQ:ALVO) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, community ranking, earnings, profitability, valuation, dividends and institutional ownership.
Pharming Group has lower revenue, but higher earnings than Alvotech. Pharming Group is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.
Alvotech has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500.
0.0% of Pharming Group shares are held by institutional investors. 0.5% of Alvotech shares are held by company insiders. Comparatively, 2.1% of Pharming Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Alvotech had 5 more articles in the media than Pharming Group. MarketBeat recorded 15 mentions for Alvotech and 10 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.67 beat Alvotech's score of 0.15 indicating that Pharming Group is being referred to more favorably in the news media.
Alvotech currently has a consensus target price of $18.00, suggesting a potential upside of 78.04%. Pharming Group has a consensus target price of $30.00, suggesting a potential upside of 159.40%. Given Pharming Group's higher possible upside, analysts plainly believe Pharming Group is more favorable than Alvotech.
Pharming Group has a net margin of -6.09% compared to Alvotech's net margin of -123.47%. Alvotech's return on equity of 0.00% beat Pharming Group's return on equity.
Pharming Group received 16 more outperform votes than Alvotech when rated by MarketBeat users. Likewise, 67.65% of users gave Pharming Group an outperform vote while only 50.00% of users gave Alvotech an outperform vote.
Summary
Pharming Group beats Alvotech on 10 of the 17 factors compared between the two stocks.
Get Pharming Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pharming Group Competitors List
Related Companies and Tools
This page (NASDAQ:PHAR) was last updated on 6/12/2025 by MarketBeat.com Staff
